Used as donor PopPK structure for the retatrutide PK bridge the BW^0.8 allometric exponent is internally validated against retatrutide in Rosenstock 2023 arm pairs (4 mg ID2 at 108.3 kg vs 4 mg ID4 at 93.1 kg: predicted Cav,ss ratio 1.13, observed 1.18, 4.8% error), so the borrowing is tirz-prior, reta-confirmed rather than tirz-substituted
However, the Medicines and Healthcare products Regulatory Agency (MHRA) has outlawed the sale of BPC-157 for human consumption in the UK
In this trial, 32% of patients were on SGLT2 inhibitor
Your provider can advise whats appropriate for you and what would actually change the plan
At Body Works, BPC-157 is compounded and used strictly under provider supervision, with an honest account of what the evidence does and does not yet establish